Saul W. Fink

Saul W. Fink, Chief Technical Officer of Q32 Bio, has more than 20 years of leadership experience with a focus on strategy and business operations across R&D and manufacturing functions. Prior to joining Q32 Bio, Dr. Fink served as Senior Vice President, Pharmaceutical and Nonclinical Development at Normunity, where he led the CMC and nonclinical teams. Previously, he was Vice President of Pharmaceutical Development and Interim Lead of Nonclinical Development at Goldfinch Bio, leading manufacturing and nonclinical development of both small molecules and biologics. Prior, Dr. Fink spent 26 years at Bristol-Myers Squibb, partnering with executive management to define CMC strategy, drive business transformations and optimize manufacturing operations. Dr. Fink received his Ph.D. in Physical/Analytical Chemistry from the University of Houston, and his B.S. in Chemistry from Millersville University where he is currently a member of the Council of Trustees as part of his extensive service on not-for-profit and local government boards. He also serves as a scientific advisory board member for Intrommune Therapeutics.